Lactotripeptides: Physiology and What Research Reports

Lactotripeptides is the collective name for two tripeptides — isoleucine-proline-proline (IPP) and valine-proline-proline (VPP) — that are released from milk proteins. They appear frequently in the nutrition and hypertension literature because they were among the first food-derived peptides studied in large numbers of randomised controlled trials. This page is for educational purposes only and is not medical advice; consult a licensed physician for questions about health, medication or blood pressure.

What Lactotripeptides Are and Where They Come From

Unlike hormones such as insulin or GLP-1, lactotripeptides are not synthesised by human endocrine tissue. They are sequence fragments buried inside casein, the dominant protein family in cow's milk. IPP corresponds to a region of β-casein and κ-casein, and VPP to a region of β-casein. Those fragments become free peptides only when the parent protein is cut, which happens in three ways described in the food-science literature:

• Microbial fermentation — proteolytic lactic acid bacteria (classically Lactobacillus helveticus) hydrolyse casein during fermentation of milk, so fermented dairy products can contain measurable IPP and VPP.
• Enzymatic hydrolysis in manufacturing — casein hydrolysates produced with food-grade proteases, used to make the standardised test products given in clinical trials of casein-derived lactotripeptides (meta-analysis of casein-derived lactotripeptide trials).
• Gastrointestinal digestion — gastric and pancreatic proteases plus brush-border peptidases acting on dietary casein.

Both peptides are proline-rich. Proline residues resist many peptidases, which is the structural reason researchers proposed that these particular tripeptides might survive digestion intact and reach the circulation — a question the critical literature has examined closely (critical review of lactotripeptides and antihypertensive effects).

The Proposed Physiology: Angiotensin-Converting Enzyme

The mechanistic hypothesis is straightforward. Angiotensin-converting enzyme (ACE) converts angiotensin I to the vasoconstrictor angiotensin II and degrades the vasodilator bradykinin; ACE has two catalytic domains, an N-terminal and a C-terminal active site. In vitro, many casein-derived peptides inhibit ACE activity, and lactotripeptides were characterised as ACE-inhibitory peptides on that basis.

Human mechanistic work has complicated that story. A human study examining ACE domain activity reported that the lactotripeptides IPP and VPP did not inhibit either the N-terminal or the C-terminal ACE active site in humans (Journal of Hypertension, 2009). That finding is one reason the peptide literature treats ACE inhibition by IPP and VPP as an in-vitro observation that has not been cleanly reproduced as an in-vivo mechanism, and why alternative explanations — effects on endothelial function, arterial stiffness or vascular tone — are discussed in later trials.

How Lactotripeptides Are Studied

Because lactotripeptides are consumed in foods and beverages rather than administered parenterally, the study designs look like nutrition trials rather than drug trials. Typical features reported in the literature include:

• Double-blind, placebo-controlled or crossover designs with a matched dairy or hydrolysate-free control product (Hypertension, 2008).
• Office blood pressure as the primary endpoint, usually systolic and diastolic pressure, pooled later in meta-analyses (NMCD, 2013).
• Ambulatory and haemodynamic endpoints — one randomised double-blind trial assessed office and 24-hour ambulatory blood pressure, blood-pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension (Hypertension Research, 2011).
• Arterial stiffness measures — a double-blind randomised crossover trial evaluated blood pressure and arterial stiffness changes in subjects with suboptimal blood pressure control and metabolic syndrome (Metabolic Syndrome and Related Disorders, 2016).
• Population stratification — separate meta-analyses were conducted for European and Japanese trial participants because pooled results appeared to differ by study region (American Journal of Hypertension, 2013) (PLoS One, 2015).

What the Literature Reports

Lactotripeptides are one of the clearest worked examples in peptide nutrition of a compound where pooled analyses and individual trials do not all point the same way.

The pattern that emerges from reading these side by side is one of heterogeneity. Several meta-analyses reported pooled blood-pressure reductions (Nutrients, 2015) (Journal of Human Hypertension, 2011), while a separate meta-analysis was published specifically to interrogate whether the same effect held in European subjects (American Journal of Hypertension, 2013) and another examined Japanese subjects separately (PLoS One, 2015). At the level of single trials, one double-blind randomised controlled trial reported no effect on human blood pressure at all (Hypertension, 2008). A critical review had already argued that the antihypertensive claims required careful appraisal of trial quality and consistency (British Journal of Nutrition, 2009).

Beyond Blood Pressure

A smaller strand of research looked at skeletal muscle rather than the vasculature. A randomised, placebo-controlled, double-blind clinical trial reported that lactotripeptide supplementation alleviated the decrease in maximal isometric force after high-intensity eccentric exercise (American Journal of Physical Medicine & Rehabilitation, 2018). That is a single-trial observation in an exercise-recovery context, not an established physiological role.

Tolerability and Adverse Events: What Studies Report

The cited literature is dominated by efficacy endpoints. The trials were run as double-blind, placebo-controlled or crossover studies using fermented-milk or casein-hydrolysate products (Hypertension, 2008) (Journal of Medicinal Food, 2010), and the published summaries of these reports centre on blood pressure, arterial stiffness and haemodynamic measures rather than on detailed adverse-event tabulations (Metabolic Syndrome and Related Disorders, 2016). A critical review of the antihypertensive literature discussed the strength and limitations of the evidence base as a whole (British Journal of Nutrition, 2009). Because a milk-protein matrix is the delivery vehicle in most studies, dairy protein allergy and lactose tolerance are relevant clinical considerations that a physician, not a literature summary, should address.

Why the Term Matters to Peptide Readers

Lactotripeptides are a useful case study for anyone learning to read peptide evidence. They show how an in-vitro enzyme-inhibition finding can generate a large clinical literature, how a human mechanistic study can fail to confirm the assumed target (Journal of Hypertension, 2009), and how pooled estimates can shift depending on which populations are included (American Journal of Hypertension, 2013). The study designs also illustrate why food-derived peptides are evaluated under nutrition-research conventions rather than pharmacological ones.

References

• Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials (American Journal of Hypertension, 2013)
• Influence of the Lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline on Systolic Blood Pressure in Japanese Subjects: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (PLoS One, 2015)
• Lactotripeptides intake and blood pressure management: a meta-analysis of randomised controlled clinical trials (Nutrition, Metabolism and Cardiovascular Diseases, 2013)
• Lactotripeptides and antihypertensive effects: a critical review (British Journal of Nutrition, 2009)
• Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials (Nutrients, 2015)
• The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans (Journal of Hypertension, 2009)
• Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials (Journal of Human Hypertension, 2011)
• Effect of Lactotripeptides (Isoleucine-Proline-Proline/Valine-Proline-Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical Trial (Metabolic Syndrome and Related Disorders, 2016)
• Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial (Hypertension Research, 2011)
• Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial (Hypertension, 2008)
• Hemodynamic effects of lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a randomized, double-blind, crossover clinical trial (Journal of Medicinal Food, 2010)
• Lactotripeptides Supplementations Alleviate the Decrease in Maximal Isometric Force After High-Intensity Eccentric Exercise: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial (American Journal of Physical Medicine & Rehabilitation, 2018)